Johnson & Johnson (NYSE:JNJ) Vision announced today that it entered into a strategic collaboration with Menicon for contact lens development. J&J Vision and Menicon are partnering to bring forward a novel portfolio of products and services to manage the progression of myopia, sometimes known as “nearsightedness,” in children, according to a news release. Menicon is […]
Optical/Ophthalmic
FDA approves Bausch + Lomb dispersive ophthalmic viscosurgical device
Bausch + Lomb announced today that it received FDA approval for its ClearVisc dispersive ophthalmic viscosurgical device (OVD). Laval, Quebec–based Bausch + Lomb — the eye health business unit of Bausch Health — developed the ClearVisc OVD for use in ophthalmic surgery to aid in cataract extraction and intraocular lens (IOL) implantation through the creation […]
Second Sight, Pixium Vision merger plans are over
Second Sight Medical notified Pixium that it decided to unilaterally terminate a memorandum of understanding (MOU) ahead of a planned merger. In a news release, Pixium said the $27.9 million private placement recently announced and closed by Second Sight was “not only explicitly prohibited under the terms of the [MOU] entered into by the companies […]
Second Sight names acting CEO
Second Sight Medical (NSDQ:EYES) announced today that it has named a new acting chief executive officer. Los Angeles-based Second Sight said in a news release that Scott Dunbar has been named by its board of directors to replace Matthew Pfeffer as acting CEO. Under Nasdaq rules, an independent director may temporarily be named acting CEO […]
Eyenovia appoints Dr. Julia Haller to board of directors
Eyenovia (NSDQ:EYEN) announced today that it appointed renowned ophthalmologist Dr. Julia Haller to its board of directors. New York–based Eyenovia adds the experienced Haller to its board as it continues to develop the MydCombi fixed-combination mydriatic agent for potential use in comprehensive eye exams with a formulation for touchless fixed-combination microdosing to improve the patient […]
J&J Vision wins Japanese approval for first drug-releasing contact lens
Johnson & Johnson Vision announced that it received approval in Japan for its Acuvue Theravision lens with Ketotifen. The company touts the lens as the first and only vision-correcting contact lens that relieves allergic eye itch through drug delivery, according to a news release. Get the full story at our sister site, Drug Delivery Business […]
Second Sight’s merger with Pixium Vision may fall through
Second Sight‘s plans to raise $27.9 million from a private placement appear to have generated conflict with its would-be owner Pixium Vision. Pixium informed Second Sight (NSDQ: EYES) yesterday that the private placement would breach the memorandum of understanding the two companies reached in early January, according to a Second Sight filing with the SEC. […]
Eyenovia partners with Eversana to commercialize pupil dilation agent
Eyenovia (NSDQ:EYEN) announced today that it partnered with Eversana to help commercialize MydCombi if it earns U.S. approval. MydCombi is a fixed-combination mydriatic agent for potential use in comprehensive eye exams with a formulation for touchless fixed-combination microdosing in an effort to improve the patient experience. The FDA earlier this month accepted Eyenovia’s New Drug Application […]
Johnson & Johnson introduces new Acuvue Oasys multifocal lens
Johnson & Johnson Vision (NYSE:JNJ) announced that it launched the Acuvue Oasys multifocal contact lenses with a pupil-optimized design. The new lens, available in the U.S. and in Canada, expands on the Acuvue Oasys portfolio to offer a new eye care option for patients with presbyopia, according to a news release. Acuvue Oasys multifocal lenses […]
Eyenovia touts study of pupil dilation treatment
Eyenovia (NSDQ:EYEN) today announced positive results from a study of its microdose array print (MAP) pupil dilation technology. Study data, published in Therapeutic Delivery, revealed pooled results from two prospective, double-masked, controlled, cross-over superiority Phase 3 studies. Those results concluded that a micro-dosed fixed-combination of tropicamide 1% and phenylephrine 2.5% for pupil dilation (mydriasis) is safe and […]
NovaSight announces pivotal trial for digital lazy eye treatment
NovaSight announced today that it is executing a large pivotal trial for its CureSight lazy eye digital treatment device. Airport City, Israel–based NovaSight’s pivotal trial has the company on track to achieving FDA 510(k) approval for the CureSight device, according to a news release. CureSight is an eye-tracking-based lazy eye treatment that NovaSight officials think […]
